@maxkrummel.bsky.social
Prof @ucsf/immunox, co-founder Solvingfor.org, partner Founderyinnovations.com, Immunologist,Immunotherapy pioneer,believer in the power of curiosity,striving to make sense of complicated things, typically enthusiastic.
Conceptualization of drugs, akin to chemical catalysts that promote sequential transitions in tissues https://authors.elsevier.com/a/1llig5TA51lD9X
How will our increasingly deep understanding of diverse immune archetypes in cancers guide our search for cures?
This perspective describes a future in which we discover drugs based on transitions of tissue/immunobiology through intermediate states, to health. authors.elsevier.com/a/1llig5TA51...
Intravital imaging of pulmonary lymphatics in #inflammation and metastatic cancer. A new imaging approach developed by Simon Cleary (@simoncleary.bsky.social), Longhui Qiu, Mark Looney and colleagues: https://buff.ly/41msQjZ
@maxkrummel.bsky.social
Discovery Stack Pilot: A Bold Experiment https://bit.ly/DiscoveryStackHome
Tired of traditional peer review?
Join the Discovery Stack Pilot study to help reshape scientific publishing!
Contribute as a Reviewer or an Author.
Learn more here: bit.ly/DiscoverySta...
#ScienceRevolution #PeerImprovement #DiscoveryStackPilot #immunosky
Many tx studies (Mujal... Azizi…)failed to validate M1/M2 signatures in vivo. Many also suspected that calling cells bearing ‘prototypical M2’ genes ‘‘immunosuppressive’ was simplistic + incorrect. Nonetheless many (us too!) leaned on the simplification. Arja addresses the reality head on…thnx JEM
02.12.2024 04:11 — 👍 27 🔁 8 💬 0 📌 0
Are so-called 'M2-like' CD206+ macrophages immunosuppressive? On the contrary, we find that they are critical for T cell mediated anti-tumor immunity. Arja Ray drove this study with help from Ken Hu, Kelly Kersten, Alexis Combes and others
www.biorxiv.org/content/10.1...
